Hyperway Pharmaceuticals
A company focused on research and development of pharmaceutical products.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | CNY100m | Series A | |
| Total Funding | 000k | ||
Related Content
Hyperway Pharmaceuticals, established in January 2019, is a biotechnology firm headquartered in Chengdu, China, concentrating on the discovery and development of small-molecule drugs. The company was founded by a team of biotech entrepreneurs and industry veterans, led by Founder, Chairman, and CEO Dr. Li Yingfu. Dr. Li brings over two decades of drug research and development and management experience from prominent pharmaceutical companies, including Bayer and Yangtze River Pharmaceutical Group. The core team includes scientists and managers with backgrounds from global and domestic pharmaceutical leaders like Bristol-Myers Squibb, Sanofi, and Wuxi PharmaTech.
The company's business model focuses on the research, development, and production of small-molecule drugs to treat a variety of diseases, particularly in the therapeutic areas of oncology, pain, and autoimmune diseases. Hyperway has established high-tech drug research platforms and possesses a particular strength in designing brain-penetrant small-molecule drugs for CNS-related diseases. A key part of its strategy involves a "two-wheel drive" approach, where the R&D of generic drugs and fine chemicals initially supports the development of its innovative drug pipeline. The company is actively seeking partners in China and internationally to co-develop its innovative medicines.
Since its inception, Hyperway has built an impressive pipeline, identifying 11 preclinical compounds (PCCs) and advancing four into clinical trials. One of its notable candidates is HBW-3220, a fourth-generation BTK inhibitor for B-cell lymphoma, which is currently in Phase I clinical studies. Other projects in clinical development include HBW-3210 and HBW-004285. The company has also received clinical trial approval for HBW-012336, an oral KRAS G12D inhibitor. The company has successfully completed several funding rounds, including an Angel round in 2019, a Series A in 2021 and a Series A+ round in 2024 that raised nearly RMB 100 million to advance its clinical trials and preclinical pipeline. Keywords: small-molecule drugs, drug discovery, oncology, autoimmune diseases, pain management, clinical trials, pharmaceutical development, BTK inhibitors, CNS diseases, drug research, biotechnology, Chengdu biotech, preclinical compounds, KRAS inhibitors, brain-penetrant drugs, pharmaceutical R&D, innovative medicines, therapeutic areas, drug development platforms, biopharmaceutical